Related coverage linked through entity extraction aliases.
Feb 18, 2026
Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to apply artificial intelligence, advanced analytics and multimodal clinical data to support drug discovery and development, marking Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company.
Feb 18, 2026
Merck and Mayo Clinic announced a research and development agreement to leverage artificial intelligence, advanced analytics, and clinical-genomic data for drug discovery and precision medicine, initially focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Feb 18, 2026
Merck partners with Mayo Clinic in a strategic research and development agreement to apply artificial intelligence and advanced analytics to drug discovery, integrating Mayo Clinic's clinical and genomic datasets with Merck's AI-enabled technologies.
Feb 17, 2026
Merck secures regulatory approvals for Keytruda in ovarian cancer and subcutaneous formulation in Canada, while launching AI-driven drug discovery partnership with Mayo Clinic targeting high-need therapeutic areas.
Feb 16, 2026
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
Feb 15, 2026
BioAsia 2026 in Hyderabad attracted over 4,000 delegates and 500 companies, featuring AI-driven drug discovery platforms and showcasing Indian biotech innovations including BioVaram's regenerative medicine breakthrough.
Feb 15, 2026
The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.
Feb 15, 2026
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
Feb 15, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and two additional collaborations totaling over $1 billion to develop treatments for immune disorders, cancer, and hearing loss gene therapies.
Feb 15, 2026
Vaxcyte has initiated its Phase 3 adult program for VAX-31, a 31-valent pneumococcal conjugate vaccine, with the pivotal OPUS-1 trial enrolling 4,000 adults aged 50 and older. The company plans to submit a Biologics License Application by the end of next year.
Feb 14, 2026
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
Feb 14, 2026
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
Feb 13, 2026
Moderna reported Q4 revenue of $678 million, beating analyst estimates, while posting a narrower-than-expected loss of $2.11 per share. The results came as the FDA refused to review the company's mRNA flu vaccine application.
Feb 13, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
Feb 12, 2026
Ligand Pharmaceuticals will release Q4 and full year 2025 financial results on February 26, 2026, following recent share price declines despite strong annual returns. The company reported annual revenue of $251.233 million and net income of $48.581 million.
Feb 13, 2026
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
Feb 13, 2026
Global pharmaceutical companies are accelerating licensing deals for China-developed experimental medicines, with deal values reaching unprecedented levels in 2026 as firms cut costs ahead of patent expirations.
May 01, 2025
The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.
Feb 12, 2026
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
